Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Emergent BioSolutions Inc. (EBS) is a Biotechnology company based in US with a market capitalization of $394.7M. Revenue declined 28.8% year-over-year and the company generated $156.8M in free cash flow. This page tracks EBS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 900 employees · IPO Nov 15, 2006
Valuation
Valuation & price
$7.94as of May 17, 2026· -42.9% vs 52w high
8.6
P/E ratio
Latest-FY diluted EPS
0.76
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$394.7M
Market cap
-28.8%
Revenue growth (YoY)
47.2%
Gross margin
$156.8M
Free cash flow (USD)
$366.7M
Net debt
0.9%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
5
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 1, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJul 2, 2026Filing
Insider Sell $25K · 10b5-1 PlanWilliams Paul Anthony · SVP, Products Business · $25.2K
- 8-K eventJun 29, 2026Filing
Contract Modification
- Insider sellMay 4, 2026Filing
Insider Sell $144K · 10b5-1 PlanZoon Kathryn C · Director · $144.5K
- Insider sellMay 4, 2026Filing
Insider Sell $128K · 10b5-1 PlanKatkin Keith · Director · $128.2K
- Insider sellMay 4, 2026Filing
Insider Sell $130K · 10b5-1 PlanDeGolyer Donald W · Director · $130K
- Insider sellMay 4, 2026Filing
Insider Sell $116K · 10b5-1 PlanDayal Sujata Tyagi · Director · $115.6K
- Quarterly reportMay 1, 2026Filing
10-Q Filed
- 8-K eventApr 30, 2026Filing
Stock Incentive Plan Amended
- 8-K eventApr 30, 2026Filing
Earnings Release
- 8-K eventApr 17, 2026Filing
Credit Agreement Amendment
Questions
Frequently asked questions
What is Emergent BioSolutions Inc.'s market cap?
Emergent BioSolutions Inc. (EBS) has a market capitalization of $394.7M.
What is EBS's P/E ratio?
EBS trades at a price-to-earnings ratio of 8.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is EBS's price-to-book (P/B) ratio?
EBS trades at 0.76 times book value per share.
Are insiders buying EBS stock?
SEC Form 4 filings show no open-market insider buys at Emergent BioSolutions Inc. in the last 90 days (5 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.